Naz Rahman
Stock Analyst at Maxim Group
(0.28)
# 4,372
Out of 5,182 analysts
38
Total ratings
18.18%
Success rate
-39.7%
Average return
Main Sectors:
Stocks Rated by Naz Rahman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VRTX Vertex Pharmaceuticals | Upgrades: Buy | $575 | $430.14 | +33.68% | 2 | Mar 18, 2026 | |
| NXGL NEXGEL | Maintains: Buy | $6 → $2 | $0.61 | +230.03% | 2 | Mar 12, 2026 | |
| SCNX Scienture Holdings | Initiates: Buy | $1.5 | $0.38 | +291.75% | 1 | Feb 24, 2026 | |
| KZIA Kazia Therapeutics | Maintains: Buy | $15 → $20 | $11.85 | +68.78% | 1 | Oct 2, 2025 | |
| AYTU Aytu BioPharma | Maintains: Buy | $9 → $7 | $2.55 | +174.51% | 2 | Sep 25, 2025 | |
| GLMD Galmed Pharmaceuticals | Downgrades: Hold | n/a | $0.59 | - | 1 | Apr 4, 2025 | |
| NVCT Nuvectis Pharma | Initiates: Buy | $17 | $8.69 | +95.63% | 1 | Apr 2, 2025 | |
| SLXN Silexion Therapeutics | Maintains: Buy | $135 → $75 | $0.64 | +11,673.94% | 2 | Mar 20, 2025 | |
| VKTX Viking Therapeutics | Maintains: Buy | $120 → $70 | $32.39 | +116.12% | 5 | Feb 7, 2025 | |
| NRSN NeuroSense Therapeutics | Downgrades: Hold | n/a | $0.81 | - | 2 | Dec 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $4.68 | - | 4 | Nov 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $23 → $8 | $1.95 | +310.26% | 7 | Nov 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $2.04 | - | 2 | Oct 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $45 | $18.04 | +149.45% | 1 | Jul 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $525 → $140 | $5.45 | +2,468.81% | 2 | Mar 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $2.85 | - | 3 | Nov 17, 2023 |
Vertex Pharmaceuticals
Mar 18, 2026
Upgrades: Buy
Price Target: $575
Current: $430.14
Upside: +33.68%
NEXGEL
Mar 12, 2026
Maintains: Buy
Price Target: $6 → $2
Current: $0.61
Upside: +230.03%
Scienture Holdings
Feb 24, 2026
Initiates: Buy
Price Target: $1.5
Current: $0.38
Upside: +291.75%
Kazia Therapeutics
Oct 2, 2025
Maintains: Buy
Price Target: $15 → $20
Current: $11.85
Upside: +68.78%
Aytu BioPharma
Sep 25, 2025
Maintains: Buy
Price Target: $9 → $7
Current: $2.55
Upside: +174.51%
Galmed Pharmaceuticals
Apr 4, 2025
Downgrades: Hold
Price Target: n/a
Current: $0.59
Upside: -
Nuvectis Pharma
Apr 2, 2025
Initiates: Buy
Price Target: $17
Current: $8.69
Upside: +95.63%
Silexion Therapeutics
Mar 20, 2025
Maintains: Buy
Price Target: $135 → $75
Current: $0.64
Upside: +11,673.94%
Viking Therapeutics
Feb 7, 2025
Maintains: Buy
Price Target: $120 → $70
Current: $32.39
Upside: +116.12%
NeuroSense Therapeutics
Dec 16, 2024
Downgrades: Hold
Price Target: n/a
Current: $0.81
Upside: -
Nov 20, 2024
Upgrades: Buy
Price Target: n/a
Current: $4.68
Upside: -
Nov 13, 2024
Maintains: Buy
Price Target: $23 → $8
Current: $1.95
Upside: +310.26%
Oct 24, 2024
Downgrades: Hold
Price Target: n/a
Current: $2.04
Upside: -
Jul 26, 2024
Initiates: Buy
Price Target: $45
Current: $18.04
Upside: +149.45%
Mar 15, 2024
Maintains: Buy
Price Target: $525 → $140
Current: $5.45
Upside: +2,468.81%
Nov 17, 2023
Downgrades: Hold
Price Target: n/a
Current: $2.85
Upside: -